For decades, pancreatic cancer and childhood leukemia have stood as two of the most daunting challenges in the world of oncology. But in a remarkable week for cancer research, new clinical trials from Northwestern University and Cincinnati Children’s Hospital are offering fresh hope to patients and families who have long faced grim prognoses. Both studies, published and announced in mid-April 2026, highlight innovative therapies that may soon reshape the landscape of cancer treatment for adults and children alike.
On April 14, 2026, a groundbreaking study published in Nature Medicine revealed that the experimental drug elraglusib, developed at Northwestern University, could significantly extend the lives of patients with metastatic pancreatic cancer. According to the study, when elraglusib was combined with standard chemotherapy, patients experienced a 38 percent reduction in the risk of death compared to those receiving chemotherapy alone. In a disease where most patients survive less than a year after diagnosis, that’s no small feat.
“Pancreatic cancer remains one of the most challenging solid tumors to treat, but these findings provide cautious optimism for patients,” said Devalingam Mahalingam, MBBChBAO, lead author of the study and professor of Medicine in the Division of Hematology and Oncology at Northwestern, as quoted by Northwestern University’s news center. Mahalingam, who also serves as associate director of clinical research at the Robert H. Lurie Comprehensive Cancer Center, emphasized the importance of these results: “While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult-to-treat cancer is encouraging.”
The phase 2 randomized trial enrolled 233 patients across 60 sites in six countries in North America and Europe. Participants were randomly assigned to receive either standard chemotherapy or the same chemotherapy paired with elraglusib. The results were striking: patients receiving elraglusib lived a median of 10.1 months, compared to 7.2 months for those on chemotherapy alone. While three months might not sound like much, in the context of metastatic pancreatic cancer, it represents a meaningful extension of life—especially for families hoping for more time together.
The survival benefit became even more pronounced over time. After one year, 44 percent of patients who received elraglusib were still alive, more than double the 22 percent survival rate in the chemotherapy-only group. At the two-year mark, about 13 percent of elraglusib patients were alive, compared to none in the chemotherapy group. As Mahalingam noted, “Given the novel mechanism of this drug, these findings raise the possibility that it could have broader application across other tumor types.”
Of course, no cancer therapy is without side effects. The trial reported that patients in the elraglusib group experienced low white blood cell counts, fatigue, and temporary vision changes. Fortunately, these side effects were generally reversible and consistent with those seen in chemotherapy, and the overall safety profile was considered manageable.
Elraglusib’s unique approach lies in its targeting of the protein GSK-3 beta, which plays a role in tumor growth and immune suppression. Unlike traditional chemotherapy, which aims to kill cancer cells directly, elraglusib appears to act on the tumor microenvironment—the complex mix of cancer cells, immune cells, and surrounding tissue. Pancreatic tumors are notoriously difficult to treat because their microenvironment is especially good at suppressing the immune system. In the study, patients receiving elraglusib showed increases in cancer-fighting cells within their tumors, suggesting the drug may help re-engage the body’s natural defenses. Certain immune-related markers in the blood at the start of the trial were also linked to longer survival among elraglusib recipients, hinting that some patients may benefit even more from this approach.
The human side of these advances is just as significant. For families like the Husars of Palos Heights, Illinois, clinical trials offered not just extra months, but hope and a sense of purpose. Donna Husar, whose late husband Matthew participated in the trial, recalled, “If you have any opportunity to go on a trial drug, go for it.” Their daughter, Madeline, echoed the sentiment: “When you read about pancreatic cancer online, it’s terrifying. But knowing there was research and a trial gave us something positive to focus on instead of stressing about the worst-case scenarios.” Maria Lepowsky, whose husband Robert Brightman also participated, said, “My husband believed in helping future patients,” and noted that the drug improved his quality of life, allowing him to maintain his autonomy for much of his treatment.
While these findings are preliminary and require confirmation in larger phase 3 trials, Mahalingam and his colleagues are optimistic. They’re already exploring further studies and considering combinations with other novel therapies to maximize clinical benefit. The study was funded by Actuate Therapeutics, with Mahalingam and Northwestern University holding financial interests in the company—a detail disclosed openly in the publication.
Meanwhile, on April 13, 2026, Cincinnati Children’s Hospital announced a strategic partnership with New Zealand-based BioOra to launch a clinical trial that could change the game for pediatric cancer patients. The trial will test Alta-cel, a third-generation CAR T-cell therapy, in children and teens with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). This is no small announcement: for years, CAR T-cell therapies have shown promise for adults, but their use in children has been limited by concerns about neurotoxicity—potentially harmful effects on the developing brain.
“Relapsed B-ALL remains one of the toughest problems in childhood cancer. The low neurotoxicity signals from the ENABLE program make Alta-cel a compelling candidate for pediatric investigation, and if that profile holds in children, it could mean bringing life-changing CAR-T therapy to more kids,” said Stella Davies, MBBS, PhD, MRCP, co-executive director of the Cancer and Blood Diseases Institute at Cincinnati Children’s, as reported by ScienceBlog. Davies, a recognized leader in pediatric hematology-oncology and President-Elect of the American Society for Transplantation and Cellular Therapy, will serve as principal investigator for the trial. The study will span multiple sites in both the U.S. and New Zealand and will be supported by the recently expanded Applied Gene and Cell Therapy Center in Sharonville, Ohio.
CAR T-cell therapy, which involves engineering a patient’s own immune cells to better recognize and destroy cancer, has already transformed outcomes for many adults. But for children, especially those with relapsed B-ALL, the risks of earlier versions have been a major barrier. Alta-cel, described as a "third-generation" therapy, aims to retain the cancer-fighting power of CAR T-cells while minimizing the neurological side effects that have plagued previous versions.
Steve Davis, MD, MMM, president and CEO of Cincinnati Children’s, has joined BioOra’s board of directors, further cementing the collaboration between the hospital and the biotech company. The hope is that, if successful, Alta-cel could unlock a new era of safer, more effective immunotherapies for children and teens facing leukemia that has resisted standard treatments.
Both of these clinical trials—one targeting one of the deadliest adult cancers, the other seeking safer, more effective options for children—underscore the ongoing evolution of cancer care. They offer not just incremental improvement, but the promise of fundamentally new strategies for some of the most difficult cancers to treat. For patients and families, these advances represent more than just scientific progress—they’re a lifeline in the face of daunting odds, and a testament to the relentless pursuit of better outcomes in cancer medicine.